Is mirtazapine an antidepressant and anxiolytic?

Mirtazapine: Antidepressant and Anxiolytic Properties

Yes, mirtazapine is both an FDA-approved antidepressant and has demonstrated anxiolytic (anti-anxiety) effects, though only the antidepressant indication is formally approved.

FDA-Approved Indication

Mirtazapine is FDA-approved specifically for the treatment of major depressive disorder (MDD) in adults 1. The drug label clearly states this as its sole approved indication, with no approval for use in children 1.

Mechanism Supporting Both Effects

Mirtazapine works as a noradrenergic and specific serotonergic antidepressant (NaSSA) through a unique mechanism 1:

• Antagonizes presynaptic α2-adrenergic receptors, enhancing both noradrenergic and serotonergic neurotransmission
• Blocks postsynaptic 5-HT2 and 5-HT3 receptors while sparing 5-HT1 receptors, which mediates serotonergic effects without typical SSRI side effects
• Antagonizes histamine H1 receptors, explaining its prominent sedative properties

This pharmacological profile provides both antidepressant and anxiolytic effects through enhanced noradrenergic and serotonergic activity 2.

Evidence for Antidepressant Efficacy

Multiple guidelines recognize mirtazapine as an effective antidepressant 3, 4, 5, 4:

• Equivalent efficacy to SSRIs and tricyclic antidepressants for treating MDD
• Faster onset of action compared to some SSRIs, with improvement noted within the first week 5
• Typical dosing: Start at 7.5-15 mg at bedtime, titrate to maximum 30-45 mg daily 3, 6
• Well-tolerated with a unique side effect profile distinct from SSRIs

Evidence for Anxiolytic Effects

While not FDA-approved for anxiety disorders, substantial evidence supports mirtazapine's anxiolytic properties:

In Depression with Comorbid Anxiety:

• A 2026 meta-analysis found mirtazapine slightly outperformed SSRIs for anxiety symptoms in MDD (SMD = -0.16, p < 0.01) 7
• In treatment-resistant depression with severe generalized anxiety, mirtazapine addition reduced GAD-7 scores significantly more than placebo (adjusted difference -2.82) 8
• Most effective in patients with severe baseline anxiety (GAD-7 ≥16), with minimal benefit in those with mild/no anxiety 8

In Primary Anxiety Disorders:

• In generalized anxiety disorder (GAD), mirtazapine performed comparably to SSRIs and benzodiazepines 7
• Open-label studies in MDD with comorbid GAD showed significant reductions in Hamilton Anxiety Scale scores within the first week 9
• The 2026 meta-analysis concluded mirtazapine "may be preferred when anxiety is relevant" and can serve as an alternative to first-line agents in GAD 7

In PTSD:

• Shows potential as an augmentation strategy when added to SSRIs 7

Clinical Positioning in Guidelines

For Depression:

• Listed as a second-generation antidepressant option alongside SSRIs and SNRIs 5, 4
• Preferred in older adults (along with citalopram, escitalopram, sertraline) due to favorable tolerability 4
• Recommended when sedation, appetite stimulation, or weight gain would be beneficial 3

For Insomnia (Off-Label):

• Recognized in sleep medicine guidelines as used off-label for insomnia at lower-than-antidepressant doses, though efficacy is "not well established" 10
• Recommended as a sedating antidepressant option when treating depression with comorbid insomnia 10
• Preferred over hypnotics in cardiovascular disease patients with depression and sleep disturbances 11

For Anxiety (Off-Label):

• Not formally recommended as first-line for primary anxiety disorders in guidelines
• However, recent evidence suggests it may serve as an alternative when SSRIs are ineffective or poorly tolerated 7

Key Clinical Considerations

Advantages:

• Rapid onset of both antidepressant and anxiolytic effects (within 1 week) 2, 9
• Improves sleep through H1 antagonism, beneficial when insomnia accompanies depression/anxiety 11, 2
• No sexual dysfunction, unlike SSRIs 2
• Well-tolerated with low cardiovascular risk 2

Common Side Effects:

• Sedation (dose-dependent, often decreases at higher doses) 3, 6
• Increased appetite and weight gain 3, 6, 2
• Dry mouth, constipation 6

Dosing Strategy:

• Start 7.5-15 mg at bedtime
• Titrate by 7.5-15 mg every 1-2 weeks based on response and tolerability
• Target dose typically 15-30 mg for anxiety effects, up to 45 mg for depression 3, 6
• Lower doses (7.5 mg) in elderly or hepatically impaired patients 3

Bottom Line

Mirtazapine is an FDA-approved antidepressant that also possesses clinically meaningful anxiolytic properties. While only approved for MDD, emerging evidence supports its use when anxiety symptoms are prominent in depression, and it may serve as an alternative in primary anxiety disorders when first-line agents fail. Its unique pharmacological profile—combining antidepressant, anxiolytic, and sedative effects without sexual dysfunction—makes it particularly valuable for patients with depression and comorbid anxiety, insomnia, or poor appetite.